Overexpression of receptor for advanced glycation end products (RAGE) in ovarian cancer.
BACKGROUND
Ovarian cancer is one of the important challenges in the field of gynecologic oncology because of some problems in understanding its etiology and pathogenesis. Receptor for advanced glycation end products (RAGE) is a multiligand trans-membranous receptor which is upregulated in some human cancers. Mechanisms of RAGE involvement in carcinogenesis of ovarian cancer are unknown.


OBJECTIVE
This study aimed to investigate the expression of RAGE in ovarian cancers and its association with clinicopathological characteristics.


METHODS
The RAGE expression level in ovarian cancer and corresponding noncancerous tissues were analyzed by real time quantitative RT-PCR and immunohistochemistry techniques.


RESULTS
Results indicated that RAGE gene was overexpressed in ovarian cancer tissue compared with adjacent noncancerous tissue (p < 0.001). A significant association between RAGE expression and tumor size (p = 0.04), depth of stromal invasion (p = 0.031), lymphovascular invasion (p = 0.041) and stage of cancer (p = 0.041) was observed. The receiver operating characteristic (ROC) analyses yielded the area under the curve (AUC) values of 0.86 for RAGE in discriminating ovarian cancer samples from non-cancer controls.


CONCLUSIONS
In conclusion overexpression of RAGE in ovarian cancer may be a useful biomarker to predict tumor progression.
Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Farzaneh
F
Rahimi
Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Jamshid
J
Karimi
Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Mohammad Taghi
MT
Goodarzi
Research Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Massoud
M
Saidijam
Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Iraj
I
Khodadadi
Iran National Tumor Bank, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
Amir Nader Emami
AN
Razavi
Department of Biochemistry, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
Maryam
M
Nankali
D000951:Antigens, Neoplasm / Q000096:biosynthesis* / Q000235:genetics; D045744:Cell Line, Tumor; D005260:Female; D015870:Gene Expression; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D020928:Mitogen-Activated Protein Kinases / Q000096:biosynthesis* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction
D000951:Antigens, Neoplasm; C498978:MOK protein, human; D020928:Mitogen-Activated Protein Kinases
Carcinoma; ovarian cancer; receptor for advanced glycation end products; tumor